Eiger Halts Phase 3 LIMT-2 Trial in Hepatitis D : vimarsana.

The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.

Related Keywords

David Apelian , , Eiger Biopharmaceuticals , Data Safety Monitoring Board , Durable Virologic Response , Discontinue Phase , Peginterferon Lambda , Chronic Hepatitis , Press Release , Metabolic Diseases , David Apelian Takes Helm , Chronic Hepatitis Delta Virus , Limt 2 , Discontinuation , Hdv , Hepatitis Delta , Phase 3 , Clinical , Trial ,